Publications in collaboration with researchers from Hospital General de Granollers (9)

2024

  1. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  2. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  3. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Vol. 55, Núm. 1, pp. 46-52

2022

  1. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  2. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

2021

  1. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851

  2. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19